Table 1. Recommendations for the management of TRD obtained from the selected CPGs.
| Recommendations | NVL CPG | VA/DoD CPG |
|---|---|---|
| 2015 [33] | 2022 [32] | |
| Augmentation drugs | R | R |
| Sequenced augmentation | NM | NM |
| Lithium | R# | NM |
| Thyroid hormone or another hormone | R* | NM |
| Psychostimulants | R* | NM |
| Dopamine | R* | NM |
| Ketamine | NM | R |
| Esketamine | NM | R |
| Switch medication | NM | NM |
| Sequence among switch | NM | NM |
| Mention specific drugs/classes | NM | NM |
| Combination | R# | NM |
| Sequence among combination | NM | NM |
| Mention specific drugs/classes | NM | NM |
| Neuromodulation | R | R |
| Sequence among neuromodulation | NM | NM |
| Electroconvulsive therapy | R | NR |
| Repetitive transcranial magnetic stimulation | NM | R |
| Deep brain stimulation | NM | NR |
| Vagal nerve stimulation | NM | CI |
| Psychotherapy | R | NM |
| Sequence among psychotherapy | NM | NM |
| Type | NM | NM |
| Evaluate the need for hospitalization | R | NM |
R = recommended; NR = not recommended; NM = not mentioned in the text; CI = mentioned in the text but contraindicated in the recommendations;
* should not be used routinely;
# not listed in the recommendations section, but mentioned in the CPG text.